Format

Send to

Choose Destination
Breast. 2013 Dec;22(6):1178-83. doi: 10.1016/j.breast.2013.08.011. Epub 2013 Sep 20.

Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.

Author information

1
Regional Oncology Center, Aleja Zwycięstwa 31/32, Gdańsk 80-219, Poland. Electronic address: ksosna@gumed.edu.pl.

Abstract

BACKGROUND:

There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast cancer (MBC).

METHODS:

The study included 198 MBC patients (96 with and 102 without BM). Using tissue microarrays derived from the primary tumor, we assessed by immunohistochemical expression of ER, PR, HER2, Ki-67, CK5/6, EGFR, HER3, CXCR4, Rad51, E-cadherin, and claudin 3 and 4.

RESULTS:

Ki-67 ≥14% (hazard ratio [HR] 2.76; P < 0.001), cytoplasmic expression of Rad51 (HR 1.87; P = 0.014) and ER-negativity (HR 1.72; P = 0.029) were associated with increased risk of BM in the multivariate analysis. A three-biomarker profile including ER, Ki-67 and Rad51 vs. other subtypes combined yielded an HR of 4.43 (P < 0.001).

CONCLUSIONS:

ER-negativity, cytoplasmic expression of Rad51 and high Ki-67 are associated with increased risk of BM.

KEYWORDS:

Brain metastases; Breast cancer; Estrogen receptor; HER2; Ki-67; Rad51

PMID:
24060578
DOI:
10.1016/j.breast.2013.08.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center